N/A N=45 Preparing Medical Students to Undertake a First Female Pelvic Exam.
Female Pelvic Exam
Primary: Score on Pelvic Exam Assessment Tool — 23.9 points
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=42 DilaCheck Cervical Dilation Measurement Trial
Cervical Dilation · Labor Pain · Labor Fast
Primary: Interexaminer Agreement — 9; 4 Participants
N/A N=30 Sound Check-Correlation Between Transperineal and Digital Cervical Exam in 3rd Trimester Pregnancy
Cervix; Pregnancy
Primary: Correlation of Cervical Dilation Via Butterfly iQ Pocket Ultrasound in Centimeters — 5.1; 5 centimeters — p=.0001
N/A N=351 Point of Care Diagnosis of Vaginal Infections
Vaginitis · Bacterial Vaginosis · Yeast Vaginitis
Primary: Number of Participants Prescribed Appropriate Treatment — 61; 104; 58; 21 Participants — p=<.001
N/A N=482 Clinical Evaluation of Effects of an Investigational Tampon on Vaginal Microflora
Vaginal Microflora
Primary: Percentage of Subjects Showing Unfavorable Changes in Primary Microflora — 52.7; 52.9; 60.0 Percentage of Participants
Phase 4 N=10 Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA
Vulvovaginal Atrophy · Dyspareunia
Primary: Visible Changes to the Vulva, Vestibule and Vaginal Region on Photography — 8 points improvement on VGTA scale — p=0.05
N/A N=147 Utilization of the Mirror During Pelvic Exams
Pelvic Exam
Primary: Group Difference in Visual Analog Scale (VAS) on Level of Vulnerability — 13.294; 16.145 mm — p=0.270
N/A N=1,105 Female Patient Preferences Regarding Physician Gender
Female Patient Preference
Primary: Proportion of Female Respondents Having Their Preferences Based on Physician Gender for the OB/GYN Care — 667; 87; 261 Participants
N/A N=94 In-use Study of Four Different Tampons
Menstruation
Primary: Tolerance of Tampon Wear Via Physician Assessment of Vaginal Health — 0; 0; 0; 0 Participants
N/A N=3,605 GARDASIL Reexamination Study (V501-059)
Human Papillomavirus (HPV) Infection
Primary: Percentage of Participants With Any Adverse Experience — 11.29 Percent of participants
N/A N=1,210 HPV Typing Between Self- and Physician-sampled
Human Papillomavirus Infection · Self Sampling · Vaginal Discharge
Primary: Agreement in the Detection of High-risk HPV Type in Physician-sampled Specimen and Self-collected Specimen. — 581; 611; 589; 559 Participants
N/A N=1,585 Clinical Study of a Diagnostic Device for NG, TV and CT in Women
Chlamydial Infection · Gonococcal Infection · Trichomoniasis
Primary: The i) Percent Sensitivity and ii) Percent Specificity of Click Device for Detection of Chlamydia Trachomatis (CT) in Self-collected Vaginal Specimens as Compared to PIS…
N/A N=24 Clinical Performance of a Vaginal Pessary (pHyph) in Bacterial Vaginosis
Bacterial Vaginosis
Primary: Clinical Cure Rate — 18 Participants
N/A N=26 Clinical Performance of the Gedea Pessary in Adult Women With Vulvovaginal Candidiasis
Vulvovaginal Candidiasis
Primary: Clinical Cure Rate at Day 7-14 — 10; 16 Participants
N/A N=23 Clinical Performance of a Vaginal Pessary (pHyph) in Vulvovaginal Candidiasis
Vulvovaginal Candidiasis
Primary: Clinical Cure Rate — 9 Participants
N/A N=98 Rapid Diagnostic Assay for Gonorrhea and Chlamydia
Urethritis · Cervicitis · Sexually Transmitted Infections
Primary: Mean Antibiotic Days of Therapy (DOT) Administered Per Patient With Symptomatic Urethritis or Cervicitis — 7; 1 Antibiotic days of therapy (DOT) — p=0.053
N/A N=50 Clinical Investigation To Evaluate Cerviron Ovules® in Symptomatic Vaginitis
Vaginitis and Vulvovaginitis
Primary: Number of Participants With the Same Gynaecological Conditions at the End of Treatment Visit — 13 Participants
N/A N=45 Coherence Imaging of the Cervical Epithelium With Scanning a/LCI
Cervical Dysplasia
Primary: Sensitivity of Scanning a/LCI Probe to Detect Cervical Dysplasia as Measured by Percentage of Correctly Identified Positive Biopsies — 90.3; 100.0 percentage of correct…
N/A N=7 A Trial to Evaluate Natural Orifice Transvaginal Endoscopic Cholecystectomy With Laparoscopic Assistance
Gallbladder Disease
Primary: Procedure Completion — 7 participants
N/A N=519 A Validation Study of Genzyme Diagnostics OSOM Trichomonas Rapid Test and BVBlue Test
Bacterial Vaginosis · Urogenital Infection by Trichomonas Vaginalis
Primary: Sensitivity of the OSOM Rapid Test and PCR Wet Mount Microscopy in Diagnosing Trichomonas Vaginalis in Symptomatic and Asymptomatic Women — 92; 91; 100; 100 Percentage…
N/A N=634 Transabdominal and Transvaginal Sonography in Medical Abortion
Abortion Early
Primary: Percentage of Subjects in Each Ultrasound Group With Additional Testing — 63; 14 Participants
Phase 3 N=2,003 Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects
Infections, Papillomavirus
Primary: Number of Subjects With HPV DNA in Cervical Samples by Hybrid Capture 2 Test (HCII) — 615; 828; 24; 418 Participants
N/A N=328 Diagnostic Accuracy of "Three Rings Vulvoscopy" for Detection of Vulvar Dermatosis
Lichen Sclerosus · Lichen Planus · Lichen Simplex Chronicus
Primary: Diagnostic Accuracy of "Three Rings Vulvoscopy" by the "Vulvoscopy Index" for Detection of Vulvar Dermatosis — 72; 0; 10; 246 Participants — p=0.6108
Phase 2 N=198 Feasibility of Delphi Screener for Cervical Cytology
Cervical Neoplasia
Primary: Sensitivity and Specificity — 0.86; 0.80 % of participants correctly diagnosed
N/A N=756 Pap Smear Collection With the Papette Brush
Cervical Cancer Screening
Primary: Specimen Adequacy — 335; 371 Participants — p=.75
N/A N=16 Clinical Analysis of Pain After Hysterectomy
Postoperative Pain
Primary: Type of Chronic Pain After Hysterectomy — 5; 4; 6; 1 participants
Phase 3 N=1,365 Bacterial Vaginosis Home Screening to Prevent STDs
Bacterial Vaginosis
Primary: One-year Incidence of Chlamydial and Gonococcal Infections in Women Who Receive Screening (Every 2 Months) and Treatment for Asymptomatic Bacterial Vaginosis as Compared…
N/A N=990 Study to Assess Outcomes in Women Undergoing Either Hysteroscopic Sterilization (Essure®) or Laparoscopic Tubal Sterilization
Contraception
Primary: Proportion of Subjects Reporting AEs of Chronic Lower Abdominal and/or Pelvic Pain After Insertion of Essure System or After Laparoscopic Tubal Sterilization — 39; 28…
Phase 3 N=2,235 Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral Contraceptive
Contraception
Primary: Annualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 14 Days Post-Last Combination Dose When Defining "On Drug" Pregnancy — 2.44; 2.42; 1.77…
N/A N=100 SIS Versus Office Hysteroscopy for Uterine Cavity Evaluation Prior to IVF
Infertility
Primary: Patient Satisfaction — 4.92; 4.84 units on a scale — p=0.57